|Mr. Daniel Tassé||CEO & Director||N/A||N/A||1960|
|Dr. Pierre-Henri Benhamou||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1955|
|Mr. David Schilansky||Deputy CEO & CFO||N/A||N/A||1975|
|Dr. Laurent Martin||Deputy CEO & Responsible Pharmacist||N/A||N/A||1967|
|Dr. Hugh A. Sampson||Chief Scientific Officer & Member of Scientific Advisory Board||N/A||N/A||1949|
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
DBV Technologies S.A.’s ISS governance QualityScore as of 25 June 2019 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder rights: 1; Compensation: 10.